Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

Nature reviews. Clinical oncology - 1 Jun 2009

Linardou Helena, Dahabreh Issa J, Bafaloukos Dimitrios, Kosmidis Paris, Murray Samuel

Abstract excerpt

Early clinical studies of tyrosine kinase inhibitors (TKIs) that target the EGFR in patients with advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced rapid, durable, complete or partial responses. These data were the basis for attempts to identify specific subgroups of patients who would further benefit from these agents. The discovery of somatic mutations in EGFR that correlated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to KRAS gene

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 19483740
DOI: 10.1038/nrclinonc.2009.62

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.PMID 19483740Read ↗

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.Semantic proximity Read ↗

EGFR Mutations and Lung CancerSemantic proximity Read ↗

Biological and clinical implications of EGFR mutations in lung cancer.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Semantic proximity Read ↗

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.Semantic proximity Read ↗

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Semantic proximity Read ↗

Review. EGFR mutations in non-small cell lung cancer--clinical implications.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact.Semantic proximity Read ↗

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer.Semantic proximity Read ↗

EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.